Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

from http://www.otonomy.com/about-us/our-story/

Patents 233show all

  • 114
    A61K - Preparations for medical, dental, or toilet purposes
  • 14
    Y02A - Technologies for adaptation to climate change
  • 13
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 10
    C07K - Peptides
  • 5
    A61M - Devices for introducing media into, or onto, the body
  • 3
    C12N - Microorganisms or enzymes
  • 2
    A61B - Diagnosis
  • 2
    A61F - Filters implantable into blood vessels
  • 1
    A61N - Electrotherapy

Clinical Trials 30show all

18Phase 38Phase 22Phase 12Phase 1/Phase 2

SEC Filings show all


45
8-K

17
10-Q

6
10-K

2
D

1
S-1

Contact Information

6275 Nancy Ridge Drive Suite 100
San Diego, CA 92121
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$153,437,00051-1002014-04-30Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2010-06-11$10,000,000Series AAvalon Ventures
2013-09-04$45,900,000Series COrbiMedOUP (Osage University Partners), Aperture Venture Partners, Novo Ventures, RiverVest, Avalon Ventures, TPG Biotech, Domain Associates
2014-04-30$49,000,000Series DJennison Associates, Perceptive Advisors, OUP (Osage University Partners), Aperture Venture Partners, RiverVest, Domain Associates, Ally Bridge Group, TPG Biotech, Novo Ventures, OrbiMed, Avalon Ventures, Federated Investors
2010-09-02$10,037,000Series Unknown
2010-08-30$38,500,000Series BNovo Ventures, RiverVestDomain Associates, TPG Biotech

SEC Form D Funding Events

DateOfferedSoldType
2011-06-02$38,844,352$24,214,701Equity
2010-06-09$26,000,000$10,567,046Equity

Key Executives

  • Jay Lichter, Ph.D.
    Executive Officer, Director
  • Paul Cayer
    Executive Officer
  • Carl LeBel, Ph.D.
    Executive Officer
  • Douglas Downs
    Executive Officer
  • Court Turner
    Director
  • Jeffrey Harris, M.D., Ph.D.
    Director
  • David Weber
    Executive Officer, Director
  • Carl LeBel
    Executive Officer
  • Gerald Wroblewski
    Executive Officer
  • Peter Bisgaard
    Director
  • Brian Dovey
    Director
  • Jeffrey Harris
    Director
  • Jay Lichter
    Director
  • John McKearn
    Director
  • Heather Preston
    Director